全州范围实施肾脏支持治疗的经济学评价
该经济学评价基于澳大利亚新南威尔士州2015年7月1日至2019年6月30日的联动患者数据,比较全州实施肾脏支持治疗(KSC)前后的费用与生存。KSC覆盖终末期肾病(ESKD)透析或保守治疗患者比例从2015至2016年的5%(n=443)升至2018至2019年的16%;
要点
- KSC覆盖ESKD透析或保守治疗患者比例从2015至2016年的5%(n=443)升至2018至2019年的16%。
- KSC估计使生存延长3至21周,取决于患者特征。
研究设计与样本
- 基于澳大利亚新南威尔士州公共卫生系统联动数据集的经济学评价,数据来自住院与非住院患者数据、急诊就诊和死亡登记。
- 比较2015年7月1日至2019年6月30日数据与2015至2016财年全州KSC实施前的常规治疗。
- 成本效益分析模型估计KSC当前经济价值(2015年7月1日至2019年6月30日)并预测至2030年6月30日不同情景下的价值。
主要发现
- 接受KSC的ESKD患者比例从2015至2016年的5%(n=443)增至2018至2019年的16%。
- KSC估计使生存延长3至21周,取决于患者特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This evaluation explored the economic value of kidney supportive care (KSC) in patients with end-stage kidney disease (ESKD) receiving dialysis or conservative management for ESKD in the public health system of New South Wales, Australia. METHODS: Deidentified patient-level data were extracted from a linked dataset of admitted and nonadmitted patient data, emergency department episodes, and death registrations. Data between 1 July 2015 and 30 June 2019 were compared with usual treatment prior to statewide KSC implementation in the 2015-2016 financial years. A cost-benefit analysis model estimated the current economic value of KSC (1 July 2015 to 30 June 2019) and projected value to 30 June 2030 under different scenarios. RESULTS: The proportion of all patients with ESKD receiving KSC increased from 5% in 2015 to 2016 (n = 443) to 16% by 2018 to 2019. Over this period, KSC was estimated to increase survival by 3 to 21 weeks, depending on patient characteristics. Projections showed that continued delivery of KSC, with ESKD treatment modality patterns and costs remaining stable, would deliver a net economic benefit of A$ 109 million through avoided costs of care and return on investment (ROI) of 212%. When adjusted to include survival improvements attributable to KSC, the net economic benefit increased to A$ 275 million (ROI: 535%). CONCLUSION: Economic evaluation of the statewide KSC service showed survival benefits and a net economic benefit 4 years after implementation. Net economic value over 10 years was estimated at A$ 275 million, which would increase with greater participation of patients with ESKD suitable for KSC.
引用
- Brady LL, Hutton A, Chapman JR, et al. Economic Evaluation of System-Wide Implementation of Kidney Supportive Care. Kidney Int Rep. 2025. PMID: 40814623. doi:10.1016/j.ekir.2025.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。